{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:35:08Z","timestamp":1794612908016,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974370"],"award-info":[{"award-number":["81974370"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gemcitabine is the first-line treatment for locally advanced and metastatic gallbladder cancer (GBC), but poor gemcitabine response is universal. Here, we utilize a genome-wide CRISPR screen to identify that loss of ELP5 reduces the gemcitabine-induced apoptosis in GBC cells in a P53-dependent manner through the Elongator complex and other uridine 34 (U<jats:sub>34<\/jats:sub>) tRNA-modifying enzymes. Mechanistically, loss of ELP5 impairs the integrity and stability of the Elongator complex to abrogate wobble U<jats:sub>34<\/jats:sub> tRNA modification, and directly impedes the wobble U<jats:sub>34<\/jats:sub> modification-dependent translation of hnRNPQ mRNA, a validated P53 internal ribosomal entry site (IRES) <jats:italic>trans<\/jats:italic>-acting factor. Downregulated hnRNPQ is unable to drive P53 IRES-dependent translation, but rescuing a U<jats:sub>34<\/jats:sub> modification-independent hnRNPQ mutant could restore P53 translation and gemcitabine sensitivity in <jats:italic>ELP5<\/jats:italic>-depleted GBC cells. GBC patients with lower ELP5, hnRNPQ, or P53 expression have poor survival outcomes after gemcitabine chemotherapy. These results indicate that the Elongator\/hnRNPQ\/P53 axis controls gemcitabine sensitivity in GBC cells.<\/jats:p>","DOI":"10.1038\/s41467-019-13420-x","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T11:37:14Z","timestamp":1575286634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Sunwang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-3154","authenticated-orcid":false,"given":"Xince","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8811-8542","authenticated-orcid":false,"given":"Man","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-8845","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"13420_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66, 271\u2013289 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"13420_CR2","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal, R. & Shaffer, E. A. Gallbladder cancer: epidemiology and outcome. Clin. Epidemiol. 6, 99\u2013109 (2014).","journal-title":"Clin. Epidemiol."},{"key":"13420_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jhep.2015.08.007","volume":"63","author":"DG Lee","year":"2015","unstructured":"Lee, D. G. et al. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression. J. Hepatol. 63, 1429\u20131439 (2015).","journal-title":"J. Hepatol."},{"key":"13420_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum, Y., Na\u2019ara, S. & Gil, Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist. Updat. 23, 55\u201368 (2015).","journal-title":"Drug Resist. Updat."},{"key":"13420_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"13420_CR6","first-page":"Cd011746","volume":"4","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman, O., Elsayed, Z. & Elhalawani, H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst. Rev. 4, Cd011746 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"13420_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.178","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang, H. et al. miR-218-5p restores sensitivity to gemcitabine through PRKCE\/MDR1 axis in gallbladder cancer. Cell Death Dis. 8, e2770 (2017).","journal-title":"Cell Death Dis."},{"key":"13420_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.bbrc.2015.07.080","volume":"464","author":"T Nakano","year":"2015","unstructured":"Nakano, T. et al. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK. Biochem. Biophys. Res. Commun. 464, 1084\u20131089 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"13420_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12013-014-0061-y","volume":"70","author":"Y Li","year":"2014","unstructured":"Li, Y., Huang, X., Huang, Z. & Feng, J. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt\/mTOR pathway. Cell Biochem. Biophys. 70, 1337\u20131342 (2014).","journal-title":"Cell Biochem. Biophys."},{"key":"13420_CR10","first-page":"521","volume":"7","author":"C Yang","year":"2014","unstructured":"Yang, C. et al. Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine. Int. J. Clin. Exp. Pathol. 7, 521\u2013528 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"13420_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nmeth1006-777","volume":"3","author":"CJ Echeverri","year":"2006","unstructured":"Echeverri, C. J. et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods 3, 777\u2013779 (2006).","journal-title":"Nat. Methods"},{"key":"13420_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"13420_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"13420_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"13420_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature13166","volume":"509","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y. et al. High-throughput screening of a CRISPR\/Cas9 library for functional genomics in human cells. Nature 509, 487\u2013491 (2014).","journal-title":"Nature"},{"key":"13420_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"13420_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"13420_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-159","volume":"13","author":"M Klanova","year":"2014","unstructured":"Klanova, M. et al. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol. Cancer 13, 159 (2014).","journal-title":"Mol. Cancer"},{"key":"13420_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.307","volume":"4","author":"R Hill","year":"2013","unstructured":"Hill, R. et al. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis. 4, e791 (2013).","journal-title":"Cell Death Dis."},{"key":"13420_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla, S. K. et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell 32, 71\u201387.e7 (2017).","journal-title":"Cancer Cell"},{"key":"13420_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"13420_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature15736","volume":"528","author":"Cancer Cell Line Encyclopedia ConsortiumGenomics of Drug Sensitivity in Cancer Consortium.","year":"2015","unstructured":"Cancer Cell Line Encyclopedia Consortium & Genomics of Drug Sensitivity in Cancer Consortium.Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84\u201387 (2015).","journal-title":"Nature"},{"key":"13420_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nsmb.2234","volume":"19","author":"S Glatt","year":"2012","unstructured":"Glatt, S. et al. The elongator subcomplex Elp456 is a hexameric RecA-like ATPase. Nat. Struct. Mol. Biol. 19, 314\u2013320 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"13420_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1261\/rna.7247705","volume":"11","author":"B Huang","year":"2005","unstructured":"Huang, B., Johansson, M. J. & Bystrom, A. S. An early step in wobble uridine tRNA modification requires the Elongator complex. RNA 11, 424\u2013436 (2005).","journal-title":"RNA"},{"key":"13420_CR25","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1128\/MCB.01542-07","volume":"28","author":"MJ Johansson","year":"2008","unstructured":"Johansson, M. J., Esberg, A., Huang, B., Bjork, G. R. & Bystrom, A. S. Eukaryotic wobble uridine modifications promote a functionally redundant decoding system. Mol. Cell Biol. 28, 3301\u20133312 (2008).","journal-title":"Mol. Cell Biol."},{"key":"13420_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1173","volume":"2","author":"E van den Born","year":"2011","unstructured":"van den Born, E. et al. ALKBH8-mediated formation of a novel diastereomeric pair of wobble nucleosides in mammalian tRNA. Nat. Commun. 2, 172 (2011).","journal-title":"Nat. Commun."},{"key":"13420_CR27","doi-asserted-by":"publisher","first-page":"e1003647","DOI":"10.1371\/journal.pgen.1003647","volume":"9","author":"J Fernandez-Vazquez","year":"2013","unstructured":"Fernandez-Vazquez, J. et al. Modification of tRNA(Lys) UUU by elongator is essential for efficient translation of stress mRNAs. PLoS. Genet. 9, e1003647 (2013).","journal-title":"PLoS. Genet."},{"key":"13420_CR28","doi-asserted-by":"publisher","first-page":"32535","DOI":"10.1074\/jbc.M112.402727","volume":"287","author":"P Close","year":"2012","unstructured":"Close, P. et al. DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator. J. Biol. Chem. 287, 32535\u201332545 (2012).","journal-title":"J. Biol. Chem."},{"key":"13420_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nchembio.1610","volume":"10","author":"K Selvadurai","year":"2014","unstructured":"Selvadurai, K., Wang, P., Seimetz, J. & Huang, R. H. Archaeal Elp3 catalyzes tRNA wobble uridine modification at C5 via a radical mechanism. Nat. Chem. Biol. 10, 810\u2013812 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"13420_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0092-8674(00)00073-8","volume":"102","author":"K Oda","year":"2000","unstructured":"Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849\u2013862 (2000).","journal-title":"Cell"},{"key":"13420_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2018","unstructured":"Leppek, K., Das, R. & Barna, M. Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat. Rev. Mol. Cell Biol. 19, 158\u2013174 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"13420_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2005.07.034","volume":"123","author":"M Takagi","year":"2005","unstructured":"Takagi, M., Absalon, M. J., McLure, K. G. & Kastan, M. B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123, 49\u201363 (2005).","journal-title":"Cell"},{"key":"13420_CR33","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1038\/sj.onc.1209483","volume":"25","author":"DQ Yang","year":"2006","unstructured":"Yang, D. Q., Halaby, M. J. & Zhang, Y. The identification of an internal ribosomal entry site in the 5\u2032-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25, 4613\u20134619 (2006).","journal-title":"Oncogene"},{"key":"13420_CR34","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1084\/jem.20160397","volume":"213","author":"S Delaunay","year":"2016","unstructured":"Delaunay, S. et al. Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. J. Exp. Med. 213, 2503\u20132523 (2016).","journal-title":"J. Exp. Med."},{"key":"13420_CR35","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.cell.2015.05.022","volume":"161","author":"DD Nedialkova","year":"2015","unstructured":"Nedialkova, D. D. & Leidel, S. A. Optimization of codon translation rates via tRNA modifications maintains proteome integrity. Cell 161, 1606\u20131618 (2015).","journal-title":"Cell"},{"key":"13420_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/cdd.2012.109","volume":"20","author":"DY Kim","year":"2013","unstructured":"Kim, D. Y. et al. hnRNP Q regulates translation of p53 in normal and stress conditions. Cell Death Differ. 20, 226\u2013234 (2013).","journal-title":"Cell Death Differ."},{"key":"13420_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/onc.2012.626","volume":"33","author":"S Weingarten-Gabbay","year":"2014","unstructured":"Weingarten-Gabbay, S. et al. The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA. Oncogene 33, 611\u2013618 (2014).","journal-title":"Oncogene"},{"key":"13420_CR38","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4161\/rna.22707","volume":"9","author":"A Sharathchandra","year":"2012","unstructured":"Sharathchandra, A., Lal, R., Khan, D. & Das, S. Annexin A2 and PSF proteins interact with p53 IRES and regulate translation of p53 mRNA. RNA Biol. 9, 1429\u20131439 (2012).","journal-title":"RNA Biol."},{"key":"13420_CR39","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1128\/MCB.00365-15","volume":"35","author":"MJ Halaby","year":"2015","unstructured":"Halaby, M. J., Harris, B. R., Miskimins, W. K., Cleary, M. P. & Yang, D. Q. Deregulation of internal ribosome entry site-mediated p53 translation in cancer cells with defective p53 response to DNA damage. Mol. Cell Biol. 35, 4006\u20134017 (2015).","journal-title":"Mol. Cell Biol."},{"key":"13420_CR40","doi-asserted-by":"crossref","first-page":"51108","DOI":"10.18632\/oncotarget.17003","volume":"8","author":"JY Seo","year":"2017","unstructured":"Seo, J. Y. et al. Heterogeneous nuclear ribonucleoprotein (hnRNP) L promotes DNA damage-induced cell apoptosis by enhancing the translation of p53. Oncotarget 8, 51108\u201351122 (2017).","journal-title":"Oncotarget"},{"key":"13420_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.479","volume":"8","author":"CH Lai","year":"2017","unstructured":"Lai, C. H. et al. Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer. Cell Death Dis. 8, e2555 (2017).","journal-title":"Cell Death Dis."},{"key":"13420_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40880-018-0318-8","volume":"38","author":"M Zhan.","year":"2018","unstructured":"Zhan., M. et al. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun. 38, 48 (2018).","journal-title":"Cancer Commun."},{"key":"13420_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40880-018-0329-5","volume":"38","author":"F Zhang.","year":"2018","unstructured":"Zhang., F. et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun. 38, 60 (2018).","journal-title":"Cancer Commun."},{"key":"13420_CR44","unstructured":"Amin, M. B. et al. AJCC cancer staging manual (8th ed) (Springer Int. Publishing 2017)."},{"key":"13420_CR45","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0243-7","volume":"558","author":"F Rapino","year":"2018","unstructured":"Rapino, F. et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature 558, 605\u2013609 (2018).","journal-title":"Nature"},{"key":"13420_CR46","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3892\/ijmm.2012.1138","volume":"30","author":"SG Gray","year":"2012","unstructured":"Gray, S. G. et al. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. Int. J. Mol. Med. 30, 1505\u20131511 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"13420_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11010-014-2143-y","volume":"396","author":"D Wang","year":"2014","unstructured":"Wang, D. et al. Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma. Mol. Cell Biochem. 396, 67\u201377 (2014).","journal-title":"Mol. Cell Biochem."},{"key":"13420_CR48","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/cas.12762","volume":"106","author":"M Li","year":"2015","unstructured":"Li, M. et al. Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway. Cancer Sci. 106, 1341\u20131350 (2015).","journal-title":"Cancer Sci."},{"key":"13420_CR49","first-page":"3969","volume":"9","author":"F Zhang","year":"2015","unstructured":"Zhang, F. et al. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des. Dev. Ther. 9, 3969\u20133987 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"13420_CR50","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3892\/or.2013.2511","volume":"30","author":"J Wang","year":"2013","unstructured":"Wang, J. et al. Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo. Oncol. Rep. 30, 833\u2013841 (2013).","journal-title":"Oncol. Rep."},{"key":"13420_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11033-006-6273-5","volume":"33","author":"J Yuan","year":"2006","unstructured":"Yuan, J. et al. Cloning and characterization of the human gene DERP6, which activates transcriptional activities of p53. Mol. Biol. Rep. 33, 151\u2013158 (2006).","journal-title":"Mol. Biol. Rep."},{"key":"13420_CR52","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1038\/onc.2015.25","volume":"34","author":"V Marcel","year":"2015","unstructured":"Marcel, V., Catez, F. & Diaz, J. J. p53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene 34, 5513\u20135523 (2015).","journal-title":"Oncogene"},{"key":"13420_CR53","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/0008-5472.CAN-09-4024","volume":"70","author":"L Montanaro","year":"2010","unstructured":"Montanaro, L. et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 70, 4767\u20134777 (2010).","journal-title":"Cancer Res."},{"key":"13420_CR54","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","volume":"68","author":"CP Wardell","year":"2018","unstructured":"Wardell, C. P. et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J. Hepatol. 68, 959\u2013969 (2018).","journal-title":"J. Hepatol."},{"key":"13420_CR55","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li, M. et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat. Genet. 46, 872\u2013876 (2014).","journal-title":"Nat. Genet."},{"key":"13420_CR56","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ng.3854","volume":"49","author":"LP Vu","year":"2017","unstructured":"Vu, L. P. et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat. Genet. 49, 866\u2013875 (2017).","journal-title":"Nat. Genet."},{"key":"13420_CR57","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/2159-8290.CD-17-0831","volume":"8","author":"S Gachet","year":"2018","unstructured":"Gachet, S. et al. Deletion 6q Drives T-cell leukemia progression by ribosome modulation. Cancer Discov. 8, 1614\u20131631 (2018).","journal-title":"Cancer Discov."},{"key":"13420_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1101\/gad.1519507","volume":"21","author":"TD Kim","year":"2007","unstructured":"Kim, T. D. et al. Rhythmic control of AANAT translation by hnRNP Q in circadian melatonin production. Genes Dev. 21, 797\u2013810 (2007).","journal-title":"Genes Dev."},{"key":"13420_CR59","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1093\/nar\/gkq569","volume":"38","author":"DY Kim","year":"2010","unstructured":"Kim, D. Y., Woo, K. C., Lee, K. H., Kim, T. D. & Kim, K. T. hnRNP Q and PTB modulate the circadian oscillation of mouse Rev-erb alpha via IRES-mediated translation. Nucleic Acids Res. 38, 7068\u20137078 (2010).","journal-title":"Nucleic Acids Res."},{"key":"13420_CR60","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.molonc.2013.04.004","volume":"7","author":"S Horiguchi","year":"2013","unstructured":"Horiguchi, S. et al. Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Mol. Oncol. 7, 840\u2013849 (2013).","journal-title":"Mol. Oncol."},{"key":"13420_CR61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.canlet.2016.06.016","volume":"380","author":"J Gu","year":"2016","unstructured":"Gu, J. et al. GFRalpha2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Lett. 380, 434\u2013441 (2016).","journal-title":"Cancer Lett."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13420-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:16:35Z","timestamp":1671243395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13420-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13420"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13420-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5492"}}